| UNIVERSITY OF GENEVA Patent applications |
| Patent application number | Title | Published |
|---|
| 20110143367 | ANTIBODIES AGAINST APRIL AS BIOMARKERS FOR EARLY PROGNOSIS OF LYMPHOMA PATIENTS - The invention relates to antibodies directed against APRIL (A Proliferation Inducing TNF Ligand, also known as TALL-2), in particular the monoclonal antibody Aprily-2, hybridoma cells producing monoclonal antibody Aprily-2, and the use of a combination of an antibody against membrane-anchored APRIL and Aprily-2 in the diagnosis of B cell lymphoma resistance to treatment and the prognosis of clinical development of Diffuse Large B-Cell (DLBCL) lymphoma from high risk patients (>60 years and International Prognostic Index >2). An amino acid sequence GTGGPSQNGEGYP called Stalk, useful in the preparation of antibodies, is described. | 06-16-2011 |
| 20100014642 | COLLIMATOR - The present invention is directed to a collimator that comprises grooves or channels in the submicrometer to micrometer range. The present invention is also related to uses of a collimator and collimator holder as described herein as well as apparatuses comprising the same. | 01-21-2010 |
| 20090220452 | Method Of Producing A Modified (POLY) Peptide - This invention relates to a method of producing a modified (poly)peptide, said method comprising the step of modifying in an organic solvent a crown ether-bound (poly)peptide at one or more carboxylic groups by esterification or thioesterification and/or at the amino group of the N-terminal amino acid by amidation or alkylation. Furthermore provided are (poly)peptides and antibodies obtainable with the method of the invention as well as medical uses thereof. | 09-03-2009 |
| 20080320609 | Diabetes Model Animal - We prepared a transgene comprising human HB-EGF precursor cDNA, as a diphtheria toxin receptor gene, at the downstream of an insulin promoter, and introduced this transgene into a mouse fertilized egg, to produce a transgenic mouse of the present invention. In this mouse, human HB-EGF precursors are expressed specifically in islet beta cells, and by injection of diphtheria toxin, islet beta cells are selectively destroyed, resulting in that the mouse shows diabetes two or three days after the injection. This mouse can be utilized in screening and development of new medicines and therapy protocols for diabetes. | 12-25-2008 |
